NFS ≤ 1
1 drugsPredictive biomarker for patient selection in 1 indication
1
Approved Drugs
1
Indications
1
Companies
NFS ≤ 1 is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 1 indication including Cerebral Adrenoleukodystrophy. Explore the targeted therapies, indications, testing methods, and companies developing NFS ≤ 1 drugs below.
Search NFS ≤ 1 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting NFS ≤ 1
| Drug | Company | Therapeutic Area |
|---|---|---|
| Skysona | bluebird bio |
NFS ≤ 1 Indications
Cerebral Adrenoleukodystrophy